September 27, 2023
Contera Pharma and BDD Pharma announce dosing of first subject in a Phase 1 trial of CP-012, a novel formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, and BDD Pharma, a drug delivery company specializing in modified…
Read more
April 11, 2023
Abzu and Contera Pharma expand strategic partnership to add target identification to RNA-therapeutic design platform
Abzu® and Contera Pharma expand their strategic partnership to add drug-target identification to their seminal RNA- and siRNAs therapeutic design platform. Contera…
Read more